#Japan #Tokyo #Workplace Safety #Infectious Disease #Sakura Finetech

Collective Vaccination Initiative by Sakura Finetech Japan

In an aimed effort to bolster workplace health and safety, Sakura Finetech Japan, a total solution provider for pathology, will conduct a collective vaccination drive for employees on October 29, 2026. This initiative is a part of the company's commitment to ensure a safe work environment, particularly following the challenges posed by infectious diseases.

The company began implementing workplace vaccinations in 2013 in response to a significant rubella outbreak. This marked the beginning of their proactive approach, recognizing their social responsibility as a healthcare-related enterprise to prevent the spread of infections. Over the years, the scope of vaccinations available has expanded to cater to the needs and demographic of the employees, currently offering five types of vaccines including measles-rubella (MR), influenza, pneumococcal for adults, shingles, and the novel coronavirus, with all costs covered by the company.

Employees' Attitude Towards Vaccination

A recent survey highlights an intriguing shift in employee perspectives regarding infectious diseases. Approximately 69.4% reported a decrease in their concern about infections compared to the heightened awareness during the pandemic. This could reflect a broader societal trend as regular life begins to resume post-COVID-19, but it raises critical questions about the lasting impact of infectious diseases on public health.

The survey revealed that 30.8% of employees who previously opted for vaccinations at the workplace indicated that they might not seek vaccinations on their own if not offered at the office. The following advantages of office-based vaccination were noted:

• - Convenience: 89.7% appreciated not having to seek out a medical facility.
• - Time Saving: 77.6% valued the option to get vaccinated during working hours.
• - Motivation: 57.0% believed that having the opportunity at work would serve as a prompting factor.

These insights underline the importance of maintaining accessible vaccination options at work to promote employee health.

A Shift Toward Continuous Infection Prevention

The experience of past outbreaks, including the rubella surge, emphasizes the necessity of ongoing health measures rather than reactionary ones. Sakura Finetech Japan believes in fostering an environment where employees are routinely educated about infections and motivated to take preventative actions.

The upcoming vaccination drive is not merely a response to immediate threats but also serves as an encouragement for long-term awareness and action against infectious diseases. The company's health strategy underlines the continued relevance of awareness and preparation in public health, thereby fulfilling their role as a responsible leader in the medical industry.

Event Specifics

The collective vaccination will take place at the company's headquarters, located at:
Sakura Finetech Japan Co., Ltd.
Address: Hamacho Center Building, 2-31-1 Hamacho, Chuo-ku, Tokyo, 103-0007
Date: October 29, 2026
Time: 11:00 AM - 1:00 PM & 2:00 PM - 5:00 PM

Available vaccines include:

• - COVID-19 Vaccine
• - MR Vaccine (Measles and Rubella)
• - Influenza Vaccine
• - Adult Pneumococcal Vaccine (60 years and older)
• - Shingles Vaccine

All vaccines will be fully subsidized by the company, ensuring that employees can access them at no personal cost.

In conclusion, Sakura Finetech Japan is committed to evolving its occupational health initiatives, adapting to employee needs, and ensuring a robust strategy against infectious disease threats as part of their corporate social responsibilities.

About Sakura Finetech Japan

Sakura Finetech Japan, a subsidiary of Sakura Global Holdings, is a specialized manufacturer of devices, consumables, and reagents for pathological testing, crucial in medical diagnostics.